Efficacy of Crizotinib After Entrectinib Resistance Due to MET Polysomy in ROS1-Rearranged NSCLC: A Case Report
暂无分享,去创建一个
[1] S. Kılıçkap,et al. Crizotinib Efficacy After Progression With Entrectinib in ROS1-Positive Lung Cancer: A Case Report , 2022, Cureus.
[2] T. Wilson,et al. MET gene amplification is a mechanism of resistance to entrectinib in ROS1+ NSCLC , 2022, Thoracic cancer.
[3] Kristen L Jones,et al. Resistance Profile and Structural Modeling of Next-Generation ROS1 Tyrosine Kinase Inhibitors , 2021, Molecular Cancer Therapeutics.
[4] P. Ma,et al. Emerging insights of tumor heterogeneity and drug resistance mechanisms in lung cancer targeted therapy , 2019, Journal of Hematology & Oncology.
[5] G. Ferretti,et al. Crizotinib in c-MET- or ROS1-positive NSCLC: results of the AcSé phase II trial. , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.
[6] A. Drilon,et al. Genomic landscape of entrectinib resistance from ctDNA analysis in STARTRK-2 , 2019, Annals of Oncology.
[7] J. Ahn,et al. Entrectinib resistance mechanisms in ROS1-rearranged non-small cell lung cancer , 2019, Investigational New Drugs.
[8] R. Camidge,et al. Identifying the Appropriate FISH Criteria for Defining MET Copy Number–Driven Lung Adenocarcinoma through Oncogene Overlap Analysis , 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[9] Meijuan Huang,et al. Response to Crizotinib Observed in Lung Adenocarcinoma with MET Copy Number Gain but without a High-Level MET/CEP7 Ratio, MET Overexpression, or Exon 14 Splicing Mutations. , 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[10] A. Tsao,et al. ROS1 Rearrangements Define a Unique Molecular Class of Lung Cancers , 2012 .